全文获取类型
收费全文 | 3494277篇 |
免费 | 271591篇 |
国内免费 | 6819篇 |
专业分类
耳鼻咽喉 | 49692篇 |
儿科学 | 111787篇 |
妇产科学 | 94654篇 |
基础医学 | 491714篇 |
口腔科学 | 103035篇 |
临床医学 | 318675篇 |
内科学 | 674852篇 |
皮肤病学 | 74837篇 |
神经病学 | 284094篇 |
特种医学 | 136394篇 |
外国民族医学 | 1084篇 |
外科学 | 529401篇 |
综合类 | 83816篇 |
现状与发展 | 5篇 |
一般理论 | 1394篇 |
预防医学 | 276369篇 |
眼科学 | 83905篇 |
药学 | 261581篇 |
11篇 | |
中国医学 | 7283篇 |
肿瘤学 | 188104篇 |
出版年
2018年 | 37571篇 |
2017年 | 28716篇 |
2016年 | 31768篇 |
2015年 | 35997篇 |
2014年 | 51165篇 |
2013年 | 76933篇 |
2012年 | 104766篇 |
2011年 | 110745篇 |
2010年 | 65587篇 |
2009年 | 61946篇 |
2008年 | 104128篇 |
2007年 | 110937篇 |
2006年 | 111881篇 |
2005年 | 108539篇 |
2004年 | 104511篇 |
2003年 | 100095篇 |
2002年 | 97872篇 |
2001年 | 166526篇 |
2000年 | 171595篇 |
1999年 | 143892篇 |
1998年 | 38784篇 |
1997年 | 34265篇 |
1996年 | 33979篇 |
1995年 | 34930篇 |
1994年 | 32646篇 |
1993年 | 30252篇 |
1992年 | 114664篇 |
1991年 | 111144篇 |
1990年 | 107226篇 |
1989年 | 103558篇 |
1988年 | 95603篇 |
1987年 | 93923篇 |
1986年 | 88778篇 |
1985年 | 84721篇 |
1984年 | 63712篇 |
1983年 | 54215篇 |
1982年 | 32083篇 |
1981年 | 28621篇 |
1979年 | 58663篇 |
1978年 | 40956篇 |
1977年 | 34743篇 |
1976年 | 32535篇 |
1975年 | 34367篇 |
1974年 | 42342篇 |
1973年 | 40407篇 |
1972年 | 37861篇 |
1971年 | 34959篇 |
1970年 | 32828篇 |
1969年 | 30551篇 |
1968年 | 28059篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
Qian Zhang Larry D. Mesner Gina M. Calabrese Naomi Dirckx Zhu Li Angela Verardo Qian Yang Robert J. Tower Marie-Claude Faugere Charles R. Farber Thomas L. Clemens 《The Journal of clinical investigation》2021,131(7)
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass. 相似文献
73.
74.
Niamul Quader Antony J. Hodgson Kishore Mulpuri Anthony Cooper Rafeef Garbi 《Ultrasound in medicine & biology》2021,47(1):139-153
Developmental dysplasia of the hip is a hip abnormality that ranges from mild acetabular dysplasia to irreducible femoral head dislocations. While 2-D B-mode ultrasound (US)-based dysplasia metrics or disease metrics are currently used clinically to diagnose developmental dysplasia of the hip, such estimates suffer from high inter-exam variability. In this work, we propose and evaluate 3-D US-derived dysplasia metrics that are automatically computed and demonstrate that these automatically derived dysplasia metrics are considerably more reproducible. The key features of our automatic method are (i) a random forest-based learning technique to remove regions across the coronal axis that do not contain bone structures necessary for dysplasia-metric extraction, thereby reducing outliers; (ii) a bone segmentation method that uses rotation-invariant and intensity-invariant filters, thus remaining robust to signal dropout and varying bone morphology; (iii) a novel slice-based learning and 3-D reconstruction strategy to estimate a probability map of the hypoechoic femoral head in the US volume; and (iv) formulae for calculating the 3-D US-derived dysplasia metrics. We validate our proposed method on real clinical data acquired from 40 infant hip examinations. Results show a considerable (around 70%) reduction in variability in two key 3-D US-derived dysplasia metrics compared with their 2-D counterparts. 相似文献
75.
76.
77.
78.
79.
Rajiv V. Dave Baek Kim Alona Courtney Rachel OConnell Tim Rattay Vicky P. Taxiarchi Jamie J. Kirkham Elizabeth M. Camacho Patricia Fairbrother Nisha Sharma Christopher W. J. Cartlidge Kieran Horgan Stuart A. McIntosh Daniel R. Leff Raghavan Vidya Shelley Potter Chris Holcombe Ellen Copson Charlotte E. Coles Ramsey I. Cutress Ashu Gandhi Cliona C. Kirwan 《British journal of cancer》2021,124(11):1785
Background The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions.Methods This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting.Findings Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey.Conclusions The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.Subject terms: Breast cancer, Surgical oncology, Health care economics, Quality of life, Health policy 相似文献
80.
Ana Paula Valverde erson Camargo Ana L cia S Rodrigues 《World Journal of Psychiatry》2021,11(11):981-996
Major depressive disorder (MDD) is a disabling and highly prevalent mood disorder as well as a common cause of suicide. Chronic stress, inflammation, and intestinal dysbiosis have all been shown to play crucial roles in the patho physiology of MDD. Although conventional antidepressants are widely used in the clinic, they can take weeks to months to produce therapeutic effects. The discovery that ketamine promotes fast and sustaining antidepressant responses is one of the most important breakthroughs in the pharmacotherapy of MDD. However, the adverse psychomimetic/dissociative and neurotoxic effects of ketamine discourage its chronic use. Therefore, agmatine, an endogenous glutamatergic modulator, has been postulated to elicit fast behavioral and synaptogenic effects by stimulating the mechanistic target of rapamycin complex 1 signaling pathway, similar to ketamine. However, recent evidence has demonstrated that the modulation of the NLR family pyrin domain containing 3 inflammasome and gut microbiota, which have been shown to play a crucial role in the pathophysiology of MDD, may also participate in the antidepressant-like effects of both ketamine and agmatine. This review seeks to provide evidence about the mechanisms that may underlie the fast antidepressant-like responses of agmatine in preclinical studies. Considering the anti-inflammatory properties of agmatine, it may also be further investigated as a useful compound for the management of MDD associated with a pro-inflammatory state. Moreover, the fast antidepressant-like response of agmatine noted in animal models should be investigated in clinical studies. 相似文献